Meet a Researcher: Dr Jenny Dewing
Jenny Dewing is a postdoctoral researcher working on a Retina UK-funded project with Dr Arjuna Ratnayaka at the University of Southampton.
Search
Search results
Genetic testing: an essential topic for discussion with the IRD community
As Luxturna reaches the clinic and other gene-specific therapies for inherited retinal disease get closer to the end of the development pipeline, it is becoming ever more important that affected families can access a genetic diagnosis, potentially opening up choices around treatment and clinical trial participation.
Meet our volunteers: Cindy Peacock
“Being part of something and feeling that you are not alone,” are just two of the positive benefits Cindy Peacock says she experiences as a volunteer with Retina UK.
FAQs: Luxturna (voretigene neparvovec)
Luxturna, a gene therapy, is only for the treatment of Leber congenital amaurosis type 2 (LCA2) and severe early-onset RP caused by mutations in a specific gene called RPE65.
e-Newsletter – January 2023
Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.
RECORDING: Professionals’ Conference – 23 June 2023
A recording of the Retina UK Professionals' Conference on 23 June 2023. The Conference was held at the University of Westminster, Marylebone Campus in London and online.
e-Newsletter June 2023
Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.
New Gene Insertion Therapy for Stargard Disease in Development
SalioGen Developing Novel Gene Insertion Therapy for Stargardt disease.
Career development award
Retina UK invites expressions of interest for their inaugural career development grant call, which will result in an award of up to £1million as a strategic and targeted investment to result in a transformative impact for therapy for inherited retinal dystrophy.
Major innovation award
Retina UK invites expressions of interest to their first major innovation grant call, which will result in an award of up to £1million over five years as a strategic and targeted investment to result in transformative impact for therapy for inherited retinal dystrophy.